Carsten Denkert
0000-0002-2249-0982
Publication & Citation Trends
Publications
0 total
Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival
Cited by 0
Semantic Scholar
292MO Durvalumab in combination with neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC): Long-term analysis from the GeparNuevo trial
Cited by 4
Semantic Scholar
323P Comparison of treatment related contacts and associated quality of life in patients with HR+/HER2- metastatic breast cancer treated in the PADMA Study
Cited by 0
Semantic Scholar
320P Phase 3 study of neoadjuvant pembrolizumab (Pembro) plus chemotherapy (Chemo) followed by adjuvant pembro for early-stage TNBC: KEYNOTE-522 magnetic resonance imaging (MRI) subgroup analysis
Cited by 1
Semantic Scholar
Tailoring Treatment to Cancer Risk and Patient Preference: The 2025 St Gallen International Breast Cancer Consensus Statement on Individualizing Therapy for Patients With Early Breast Cancer.
Cited by 15
Semantic Scholar
Long-term effect of neoadjuvant denosumab treatment in high-risk early breast cancer (GeparX)
Cited by 0
Semantic Scholar
352P Long-term survival of HER2-positive breast cancer patients with brain metastases: Final analysis of the Brain Metastases in Breast Cancer Registry (BMBC)
Cited by 0
Semantic Scholar
310P Quality of life with first-line ET + palbociclib vs standard mono-chemotherapy in high risk HER2-/HR+ mBC and indication for chemotherapy in the PADMA study
Cited by 1
Semantic Scholar
Research Topics
Breast Cancer Treatment Studies
(359)
HER2/EGFR in Cancer Research
(254)
Cancer Genomics and Diagnostics
(213)
Cancer Immunotherapy and Biomarkers
(198)
Advanced Breast Cancer Therapies
(152)
Affiliations
Université Paris-Sud
Supélec
Ontario Institute for Cancer Research
Champalimaud Foundation
Goethe University Frankfurt